Revela is a pre-clinical stage Biotechnology company headquartered in Cambridge, Massachusetts. Our patented technology enables the imaging of cancer with unprecedented clarity. We create antibody fragments that when used as PET imaging agents can detect minute cancer activity. This non-invasive method tracks the cancer cells and human immune system in tumors, allowing for rapid diagnosis and enables more precise and effective treatment options for patients. Additionally our technology allows doctors to evaluate cancer immunotherapy efficacy in patients at a much earlier stage of treatment. Our goal is to bring this technology into full clinical trials and ultimately improve outcomes for patients across a broad range of cancers.
Revela Biotech aims to revolutionize cancer treatment through the use of specially-modified detection agents for PET imaging of the tumor microenvironment. Our platform technology allows real-time, in vivo detection of cancer cells, immune infiltrates, and other disease markers with molecular specificity, enabling improved diagnostics and targeted treatment plans.